Mutant p53 in colon cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) development is driven by accumulating genetic alterations in key driver genes.
• APC, KRAS, TGFBR2, and TP53 are frequently mutated in CRC, with TP53 mutations occurring in approximately 60% of cases.
• Missense mutations in TP53, often at 'hot spots', suggest a gain-of-function mechanism contributing to CRC progression.

Purpose of the Study:

• To investigate the oncogenic role of missense p53 mutations in colorectal cancer progression.
• To elucidate the mechanisms by which mutant p53 promotes tumor invasion and metastasis.
• To explore the potential of targeting mutant p53 for therapeutic intervention in advanced CRC.

Main Methods:

• Utilized mouse models to study the functional impact of specific p53 mutations (e.g., p53 R270H) on intestinal tumor invasion.
• Examined the combined effects of mutant p53 with other genetic alterations (Kras activation, TGF-β suppression) on metastasis.
• Investigated the role of p53 mutations and loss of wild-type p53 in activating inflammatory pathways like NF-κB.

Main Results:

• The p53 R270H mutation in mouse models induced submucosal invasion, an effect not observed with wild-type p53 loss alone.
• Mutant p53, in conjunction with Kras activation and TGF-β suppression, promoted tumor metastasis.
• Both missense p53 mutations and wild-type p53 loss activated NF-κB signaling, potentially driving epithelial-mesenchymal transition.

Conclusions:

• Missense p53 mutations, alongside wild-type p53 loss, significantly accelerate late-stage colorectal cancer progression.
• Activation of both oncogenic and inflammatory pathways by mutant p53 contributes to malignant advancement.
• Inhibiting mutant p53 nuclear accumulation represents a promising therapeutic strategy for advanced colorectal cancer.